For example, twice-daily subcutaneous (SC) injection of teriparatide, a recombinant PTH(1-34) analogue with a short half-life (∼1 hour) (2), was more efficacious than once-daily administration in normalizing serum calcium and reducing hypercalciuria in patients with hypoPT (9). The gene discussed is PTH; the disease is Hypercalciuria.